Polycystic kidney disease medical therapy

Jump to navigation Jump to search

Polycystic kidney disease Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Polycystic kidney disease from other Diseases

Epidemiology and Demographics

Risk Factor

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-Ray

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Interventions

Surgery

Primary Prevention

Secondary Prevention

Future or Investigational Therapies

Case Studies

Case #1

Polycystic kidney disease medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Polycystic kidney disease medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Polycystic kidney disease medical therapy

CDC on Polycystic kidney disease medical therapy

Polycystic kidney disease medical therapy in the news

Blogs on Polycystic kidney disease medical therapy

Directions to Hospitals Treating Polycystic kidney disease

Risk calculators and risk factors for Polycystic kidney disease medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief:

Overview

Treatment

Treatment of ADPKD is targeted at managing symptoms and disease complications. There have been no treatments associated with disease regression or slowing of cysts formation.[1]

Hypertension

Up to 75% of patients with ADPKD on imaging without any renal insufficiency are hypertensive.[2] Even in young patients, 50% of those aged 20-34 years are hypertensive despite normal renal function.[3] Treatment is recommended when blood pressure exceeds 130/80 mm Hg for adults, or sex and age adjusted norms for children. ACE inhibitors and ARBs are highly recommended as observational studies have shown better preservation of renal function with these agents. Eventual resistance or blunting of the effects of the these agents with increased volume retention can be encountered. Salt restriction, with addition of thiazide diuretics initially or loop diuretics as a second line, is justified.[1]

Hematuria

Gross hematuria with significant renal colic secondary to collecting system clots is not uncommon. Treatment usually involves analgesia, bed rest and hydration to increase urinary flow rate to 2-3 liters daily. In most patients, gross hematuria regresses to microscopic hematuria in a few days. Patients should be advised to avoid sports with risk of abdominal trauma to prevent recurrent episodes.[1]

Urinary Tract Infections

Women are at a higher risk for UTIs and cyst infections with gram negative rods being the most common pathogens. Symptomatic cyst infections or acute pyelonephritis require hospital admission with floroquinolone therapy until pain, fever, and leukocytosis resolve.[4]

Pain

Kidney Stones

Renal Failure

References

  1. 1.0 1.1 1.2 Grantham JJ (2008). "Clinical practice. Autosomal dominant polycystic kidney disease". N Engl J Med. 359 (14): 1477–85. doi:10.1056/NEJMcp0804458. PMID 18832246.
  2. Gabow PA (1990). "Autosomal dominant polycystic kidney disease--more than a renal disease". Am J Kidney Dis. 16 (5): 403–13. PMID 2239929.
  3. Kelleher CL, McFann KK, Johnson AM, Schrier RW (2004). "Characteristics of hypertension in young adults with autosomal dominant polycystic kidney disease compared with the general U.S. population". Am J Hypertens. 17 (11 Pt 1): 1029–34. doi:10.1016/j.amjhyper.2004.06.020. PMID 15533729.
  4. Gibson P, Watson ML (1998). "Cyst infection in polycystic kidney disease: a clinical challenge". Nephrol Dial Transplant. 13 (10): 2455–7. PMID 9794537.

Template:WH Template:WS